CoChat

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Open access
Kankanala, Jayakanth, Kirby, Karen A., Huber, Andrew D., Casey, Mary C., Wilson, Daniel J., Sarafianos, Stefan G., Wang, Zhengqiang · 2017 · European Journal of Medicinal Chemistry
Cited by 44

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC50 = 0.04 μM) with decent antiviral potency (EC50 = 7.4 μM) and no cytotoxicity (CC50 > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC50 = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2017.09.054

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 53

  1. Fuji, 2009, Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase, J. Med. Chem., 52, 1380, 10.1021/jm801071m · DOI
  2. Kirschberg, 2009, RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information, J. Med. Chem., 52, 5781, 10.1021/jm900597q · DOI · Paper page
  3. Kang, 2014, “Old dogs with new tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets, Mol. Biosyst., 10, 1998, 10.1039/C4MB00147H · DOI
  4. Cihlar, 2010, Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine, Antivir. Res., 85, 39, 10.1016/j.antiviral.2009.09.014 · DOI · Paper page
  5. de Bethune, 2010, Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009), Antivir. Res., 85, 75, 10.1016/j.antiviral.2009.09.008 · DOI · Paper page
  6. Yu, 2008, Recent advances in the research of HIV-1 RNase H inhibitors, Mini. Rev. Med. Chem., 8, 1243, 10.2174/138955708786141052 · DOI
  7. Wang, 2017, Update on recent developments in small molecular HIV-1 RNase H inhibitors (2013-2016): opportunities and challenges, Curr. Med. Chem., 24
  8. Shaw-Reid, 2003, Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-5-(benzoylamino)thien-2-yl -2,4-dioxobutanoic acid, J. Biol. Chem., 278, 2777, 10.1074/jbc.C200621200 · DOI · Paper page
  9. Klumpp, 2003, Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors, Nucleic Acids Res., 31, 6852, 10.1093/nar/gkg881 · DOI · Paper page
  10. Vernekar, 2015, Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities, J. Med. Chem., 58, 651, 10.1021/jm501132s · DOI · Paper page
  11. Tang J, 2017, Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase, Eur. J. Med. Chem., 133, 85, 10.1016/j.ejmech.2017.03.059 · DOI
  12. Himmel, 2009, Structure of HIV-1 reverse transcriptase with the inhibitor beta-thujaplicinol bound at the RNase H active site, Structure, 17, 1625, 10.1016/j.str.2009.09.016 · DOI · Paper page
  13. Williams, 2010, Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold, Bioorg. Med. Chem. Lett., 20, 6754, 10.1016/j.bmcl.2010.08.135 · DOI
  14. Beilhartz, 2014, Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation, J. Biol. Chem., 289, 16270, 10.1074/jbc.M114.569707 · DOI · Paper page
  15. Tang, 2016, 3-Hydroxypyrimidine-2,4-diones as selective active site inhibitors of HIV reverse transcriptase-associated RNase H: design, synthesis, and biochemical evaluations, J. Med. Chem., 59, 2648, 10.1021/acs.jmedchem.5b01879 · DOI
  16. Wu, 2016, 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H, J. Med. Chem., 59, 6136, 10.1021/acs.jmedchem.6b00040 · DOI
  17. Tang, 2017, 6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverse transcriptase: impacts of the 3-OH on inhibiting RNase H and polymerase, Eur. J. Med. Chem., 128, 168, 10.1016/j.ejmech.2017.01.041 · DOI
  18. Tumey, 2005, The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors, Bioorg. Med. Chem. Lett., 15, 277, 10.1016/j.bmcl.2004.10.086 · DOI
  19. Kankanala, 2016, Isoquinoline-1,3-diones as selective inhibitors of tyrosyl DNA phosphodiesterase II (TDP2), J. Med. Chem., 59, 2734, 10.1021/acs.jmedchem.5b01973 · DOI
  20. Chen, 2012, The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus, Bioorg. Med. Chem., 20, 467, 10.1016/j.bmc.2011.10.058 · DOI
  21. Lanier, 2007, Selection, synthesis, and structure-activity relationship of tetrahydropyrido 4,3-dipyrimidine-2,4-diones as human GnRH receptor antagonists, Bioorg. Med. Chem., 15, 5590, 10.1016/j.bmc.2007.05.029 · doi:10.1016/j.bmc.2007.05.029
  22. Briel, 2010, Substituted 2-aminothiopen-derivatives: a potential new class of GluR6-antagonists, Eur. J. Med. Chem., 45, 69, 10.1016/j.ejmech.2009.09.025 · doi:10.1016/j.ejmech.2009.09.025
  23. Osman, 2016, Discovery of novel tetrahydrobenzo b thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: the structural elements controlling binding affinity, selectivity and functionality, Eur. J. Med. Chem., 122, 619, 10.1016/j.ejmech.2016.07.012 · DOI
  24. Sirivolu, 2013, Clicking 3 '-azidothymidine into novel potent inhibitors of human immunodeficiency virus, J. Med. Chem., 56, 8765, 10.1021/jm401232v · DOI
  25. Himmel, 2006, HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site, ACS Chem. Biol., 1, 702, 10.1021/cb600303y · DOI · Paper page
  26. Johns, 2013, Carbamoyl pyridone HIV-1 integrase inhibitors 3. a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744), J. Med. Chem., 56, 5901, 10.1021/jm400645w · DOI · Paper page
  27. Friesner, 2006, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem., 49, 6177, 10.1021/jm051256o · DOI · Paper page
  28. Huang, 1998, Structure of a covalently trapped catalytic complex of HIV-I reverse transcriptase: implications for drug resistance, Science, 282, 1669, 10.1126/science.282.5394.1669 · DOI · Paper page
  29. Sarafianos, 2001, Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA, EMBO J., 20, 1449, 10.1093/emboj/20.6.1449 · DOI · Paper page
  30. Sarafianos, 2002, Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA, EMBO J., 21, 6614, 10.1093/emboj/cdf637 · DOI · Paper page
  31. Kirby, 2017, A 2-hydroxyisoquinoline-1,3-dione active site RNase H inhibitor binds in multiple modes to HIV-1 reverse transcriptase, Antimicrob. Agents Chemother., 61, 10.1128/AAC.01351-17 · DOI
  32. Fletcher, 1996, Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase, Protein Expr. Purif., 7, 27, 10.1006/prep.1996.0004 · DOI
  33. Parniak, 2003, A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity, Anal. Biochem., 322, 33, 10.1016/j.ab.2003.06.001 · DOI
  34. Vernekar, 2017, Double-winged 3-hydroxypyrimidine-2,4-diones: potent and selective inhibition against HIV-1 RNase H with significant antiviral activity, J. Med. Chem., 60, 5045, 10.1021/acs.jmedchem.7b00440 · DOI · Paper page
  35. Wang, 2007, Rationally designed dual inhibitors of HIV reverse transcriptase and integrase, J. Med. Chem., 50, 3416, 10.1021/jm070512p · DOI · Paper page
  36. Abram, 2005, Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain, J. Virol., 79, 11952, 10.1128/JVI.79.18.11952-11961.2005 · DOI · Paper page
  37. Sastry, 2013, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments, J. Comput. Aided Mol. Des., 27, 221, 10.1007/s10822-013-9644-8 · DOI · Paper page
  38. Jorgensen, 1996, Development and testing of the OPLS all- atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc., 118, 11225, 10.1021/ja9621760 · DOI · Paper page
  39. Kirby, 2012, Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase, Antimicrob. Agents Chemother., 56, 2048, 10.1128/AAC.06000-11 · DOI
  40. Bauman, 2008, Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design, Nucleic Acids Res., 36, 5083, 10.1093/nar/gkn464 · DOI · Paper page
  41. Winter, 2013, Decision making in xia2, Acta Crystallogr. D. Biol. Crystallogr., 69, 1260, 10.1107/S0907444913015308 · DOI · Paper page
  42. Kabsch, 2010, XDS, Acta Crystallogr. D Biol. Crystallogr., 66, 125, 10.1107/S0907444909047337 · DOI · Paper page
  43. Matthews, 1985, Determination of protein molecular-weight, hydration, and packing from crystal density, Methods Enzymol., 114, 176, 10.1016/0076-6879(85)14018-8 · DOI
  44. Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr. D. Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
  45. Keegan, 2008, MrBUMP: an automated pipeline for molecular replacement, Acta Crystallogr. D. Biol. Crystallogr., 64, 119, 10.1107/S0907444907037195 · DOI · Paper page
  46. Bauman, 2013, Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening, J. Med. Chem., 56, 2738, 10.1021/jm301271j · DOI · Paper page
  47. Cowtan, 2006, The Buccaneer software for automated model building. 1. Tracing protein chains, Acta Crystallogr. D. Biol. Crystallogr., 62, 1002, 10.1107/S0907444906022116 · DOI · Paper page
  48. Cowtan, 2010, Recent developments in classical density modification, Acta Crystallogr. D. Biol. Crystallogr., 66, 470, 10.1107/S090744490903947X · DOI · Paper page
  49. Emsley, 2010, Features and development of Coot, Acta Crystallogr. D. Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
  50. Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. D. Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
  51. Pannu, 1998, Incorporation of prior phase information strengthens maximum-likelihood structure refinement, Acta Crystallogr. D. Biol. Crystallogr., 54, 1285, 10.1107/S0907444998004119 · DOI · Paper page
  52. Murshudov, 2011, REFMAC5 for the refinement of macromolecular crystal structures, Acta Crystallogr. D. Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314 · DOI · Paper page
  53. Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D. Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073 · DOI · Paper page

Cited by

See all 44

Metadata

Authors
Kankanala, J., Kirby, K. A., Huber, A. D., Casey, M. C., Wilson, D. J., Sarafianos, S. G., & Wang, Z.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2017-12
Volume
141
Pages
149-161
ISSN
0223-5234 (ISSN-L)
OpenAlex
W2756623713
Cited by
44
References
4
FWCI
3.28
Type
journal article
Language
en
Open access
bronze
Funders
  • National Institutes of Health (AI100890)
  • Research Development and Seed Grant Program of the Center for Drug Design, University of Minnesota
  • U.S. DOE (DE-AC02-06CH11357)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.